The news is a remarkable turnaround for the drug, which had looked doomed to failure just a few months ago. In January this year, GlaxoSmithKline returned the rights to the drug following failure in Phase 3 trials.
Clinical stage biopharmaceutical company DiaMedica has completed enrollment of type 2 diabetic patients in the DM199 single ascending dose (SAD) clinical study.
Diffusion Pharmaceuticals has completed enrolling 56 patients with newly diagnosed primary brain cancer (glioblastoma multiforme or GBM) in the Phase II trial of an anti-cancer compound, trans sodium crocetinate (TSC).
Oramed Pharmaceuticals has started recruiting patients for a new clinical trial of ORMD-0801, an orally ingestible insulin capsule, for patients with type 1 diabetes mellitus (T1DM) in Israel.
Eli Lilly and Company has reported positive data from the Phase III study of Cialis/finasteride in men with lower urinary tract symptoms of benign prostatic hyperplasia (LUTS/BPH) and enlarged prostates.
Boston Therapeutics has presented positive results of its PAZ320 drug, designed for reducing post-meal elevation of blood glucose, from its Phase ll clinical trial.